Pediatric Formulary

Potassium iodide

Generic name

Potassium iodide

Brand name

ATC Code

H03CA

Compare …

Dosages

Side effects in children

Warnings & precautions in children

Contra-indications in children

Interactions

Renal impairment

References

Pharmacokinetics in children

No information

dose recommendation of formulary compared to licensed use (on-label versus off-label)

No information is present at this moment.

Available formulations

No information is present at this moment.

Dosages

Thyrotoxicosis
Oral Term neonate ^[1] 15 mg/day in 3 doses. Start administration several hours after thiamazole or propylthiouracil has been started.

Thyroid blockade during therapy with radioactive iodine
Oral Term neonate ^{[2] [3] [4]} 16.25 mg/dose, once only. Start and duration in consultation with a nuclear medicine scientist. Drops: Solutio Lugoli Forte, contains approximately 5 mg as iodine + iodide per drop. 1 month up to 3 years ^{[2] [3] [4]} 32.5 mg/day in 1 dose Depending on the radiation burden, a higher dose may be indicated. For radiation prophylaxis in older children, potassium iodide capsules are preferred. 3 years up to 12 years ^{[2] [3] [4]} 65 mg/day in 1 dose Duration of treatment: Start 2 days before administration of the radiopharmaceutical, up to and including Day 7 after (total 10 days); At therapeutic radiation doses, an earlier start may be desirable – consult a nuclear medicine scientist. ≥ 12 years ^{[2] [3] [4]} 130 mg/day in 1 dose Duration of treatment: Start 2 days before administration of the radiopharmaceutical, up to and including Day 7 after (total 10 days) At therapeutic radiation doses, an earlier start may be desirable – consult a nuclear medicine scientist

Thyroid blockade during therapy with radioactive iodine

Oral
- Term neonate
  ^{[2]
  
  [3]
  
  [4]}
  - 16.25 mg/dose, once only.
  - Start and duration in consultation with a nuclear medicine scientist.
    Drops: Solutio Lugoli Forte, contains approximately 5 mg as iodine + iodide per drop.
- 1 month up to 3 years
  ^{[2]
  
  [3]
  
  [4]}
  - 32.5 mg/day in 1 dose
  - Depending on the radiation burden, a higher dose may be indicated. For radiation prophylaxis in older children, potassium iodide capsules are preferred.
- 3 years up to 12 years
  ^{[2]
  
  [3]
  
  [4]}
  - 65 mg/day in 1 dose
  - Duration of treatment:
    Start 2 days before administration of the radiopharmaceutical, up to and including Day 7 after (total 10 days);
  - At therapeutic radiation doses, an earlier start may be desirable – consult a nuclear medicine scientist.
- ≥ 12 years
  ^{[2]
  
  [3]
  
  [4]}
  - 130 mg/day in 1 dose
  - Duration of treatment:
    Start 2 days before administration of the radiopharmaceutical, up to and including Day 7 after (total 10 days)
  - At therapeutic radiation doses, an earlier start may be desirable – consult a nuclear medicine scientist

Radioactive iodine exposure in nuclear disaster
Oral Term neonate ^[2] 16.25 mg/dose, once only. Administer the tablets as soon as possible and preferably within 2 hours of the anticipated start of exposure. However, an administration up to 8 hours after the estimated start of exposure is still appropriate. 16,25 mg potassium iodide corresponds to 12,5 mg iodine Drops: Solutio Lugoli Forte, contains approximately 5 mg as iodine + iodide per drop. 1 month up to 3 years ^[2] 32.5 mg/dose in 1 dose Administer the tablets as soon as possible and preferably within 2 hours of the anticipated start of exposure. However, an administration up to 8 hours after the estimated start of exposure is still appropriate. Once daily as long as exposure persists 32,5 mg potassium iodide corresponds to 25 mg iodine Drops: Solutio Lugoli Forte, contains approximately 5 mg as iodine + iodide per drop. 3 years up to 12 years ^[2] 65 mg/dose in 1 dose Administer the tablets as soon as possible and preferably within 2 hours of the anticipated start of exposure. However, an administration up to 8 hours after the estimated start of exposure is still appropriate. Once daily as long as exposure persists 65 mg potassium iodide corresponds to 50 mg iodine Drops: Solutio Lugoli Forte, contains approximately 5 mg as iodine + iodide per drop. 12 years up to 18 years ^[2] 130 mg/dose in 1 dose Administer the tablets as soon as possible and preferably within 2 hours of the anticipated start of exposure. However, an administration up to 8 hours after the estimated start of exposure is still appropriate. Once daily as long as exposure persists 130 mg potassium iodide corresponds to 100 mg iodine Drops: Solutio Lugoli Forte, contains approximately 5 mg as iodine + iodide per drop.

Radioactive iodine exposure in nuclear disaster

Oral
- Term neonate
  ^[2]
  - 16.25 mg/dose, once only.
  - - Administer the tablets as soon as possible and preferably within 2 hours of the anticipated start of exposure. However, an administration up to 8 hours after the estimated start of exposure is still appropriate.
    - 16,25 mg potassium iodide corresponds to 12,5 mg iodine
    Drops: Solutio Lugoli Forte, contains approximately 5 mg as iodine + iodide per drop.
- 1 month up to 3 years
  ^[2]
  - 32.5 mg/dose in 1 dose
  - - Administer the tablets as soon as possible and preferably within 2 hours of the anticipated start of exposure. However, an administration up to 8 hours after the estimated start of exposure is still appropriate.
    - Once daily as long as exposure persists
    - 32,5 mg potassium iodide corresponds to 25 mg iodine
    Drops: Solutio Lugoli Forte, contains approximately 5 mg as iodine + iodide per drop.
- 3 years up to 12 years
  ^[2]
  - 65 mg/dose in 1 dose
  - - Administer the tablets as soon as possible and preferably within 2 hours of the anticipated start of exposure. However, an administration up to 8 hours after the estimated start of exposure is still appropriate.
    - Once daily as long as exposure persists
    - 65 mg potassium iodide corresponds to 50 mg iodine
    Drops: Solutio Lugoli Forte, contains approximately 5 mg as iodine + iodide per drop.
- 12 years up to 18 years
  ^[2]
  - 130 mg/dose in 1 dose
  - - Administer the tablets as soon as possible and preferably within 2 hours of the anticipated start of exposure. However, an administration up to 8 hours after the estimated start of exposure is still appropriate.
    - Once daily as long as exposure persists
    - 130 mg potassium iodide corresponds to 100 mg iodine
    Drops: Solutio Lugoli Forte, contains approximately 5 mg as iodine + iodide per drop.

Renal impaiment in children > 3 months

GFR ≥10 ml/min/1.73m2: Dose adjustment not required.

GFR <10 ml/min/1.73m2: A general recommendation on dose adjustment cannot be provided.

The complete list of all undesirable drug reactions can be found in the national Summary of Product Characteristics (SmPC) – click here

Side effects

No information is present at this moment.

The complete list of all contra-indications can be found in the national Summary of Product Characteristics (SmPC) – click here

Contra-indications

No information available on specific contra indications in children.

The complete list of all warnings and precautions can be found in the national Summary of Product Characteristics (SmPC) – click here

Warnings & precautions in children

The risk of exposure to radioactive iodine and of excessive potassium iodide blocking the thyroid function is particularly high in neonates in the first days of life. The fraction of radioactive iodine taken up is four times greater in them than in any other age group. The thyroid glands of neonates are particularly susceptible to functional blockage due to excessive potassium iodide. Transient hypothyroidism during this period of early brain development may result in loss of intellectual capacity. If stable iodine is given to neonates, it is crucial that the thyroid function is closely monitored. For neonates who are given potassium iodide during the first weeks of life, the TSH and (if necessary) T4 content should be monitored and appropriate replacement therapy should be provided.

The potential benefit of iodine prophylaxis is greatest among younger individuals.
The thyroid gland of a foetus, infant or young child has a higher annual thyroid cancer risk per unit dose of radioactive iodine than the thyroid gland of an adult.

Interactions

The complete list of all interactions can be found in the national Summary of Product Characteristics (SmPC) – click here

SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS

THYROID THERAPY

This pages provides a list of drugs from the same ATC class for comparison. This does not necessarily mean that these drugs are interchangeable.

THYROID PREPARATIONS
	Levothyroxine Related Medicines Menu">	H03AA01

ANTITHYROID PREPARATIONS
	Carbimazol Related Medicines Menu">	H03BB01
	Propylthiouracil Related Medicines Menu">	H03BA02
	Thiamazole Related Medicines Menu">	H03BB02

References

Rademaker C.M.A. et al, Geneesmiddelen-Formularium voor Kinderen, 2007
G.L. Pharma GmbH, SmPC Kajodan (RVG 109973) 06-10-2021, www.geneesmiddeleninformatiebank.nl
National Radiological protection Board 2nd UK Working Group on Stable Iodine Prophylaxis, Stable Iodine Profylaxis, NRPB publications, 2001, 12 (3)
FDA, Potassium Iodide as a Thyroid Blocking Agent in Radiation Emergencies, 2001
Online GL. Gelbe Liste Online, https://www.gelbe-liste.de/, Accessed April 15, 2019
AVOXA ABDA-Datenbank, Wirkstoffdossiers Kaliumiodid, accessed 2018-07
Lindopharm, SmPC Jodinat 100 µg/200 µg Tabletten (64628.00.00), 11/2013
Hennig, SmPC Jodetten 100µg/150µg/200µg/1530µg Tabletten (41411.01.00), 12/2018

Potassium iodide

Potassium iodide

Potassium iodide

Pharmacokinetics in children

dose recommendation of formulary compared to licensed use (on-label versus off-label)

Available formulations

Dosages

Renal impaiment in children > 3 months

Side effects

Contra-indications

Warnings & precautions in children

Interactions

THYROID THERAPY

References

Changes

Therapeutic Drug Monitoring

Overdose